Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductases thereby increasing the production of benzylisoquinoline alkaloids and/or benzylisoquinoline alkaloid precursors.

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to have reduced levels or activity of one or more alcohol dehydrogenases or aldehyde reductases thereby increasing the production of benzylisoquinoline alkaloids and/or benzylisoquinoline alkaloid precursors.

The present invention relates to a method for promoting acetylglucosamine synthesis of Bacillus subtilis, which belongs to the field of genetic engineering. The present invention adopts the recombinant Bacillus subtilis BSGNKAP2 as a starting strain, exogenously introducing pyruvate carboxylase BalpycA derived from Bacillus cereus, eliminating the central carbon metabolism overflow of the Bacillus subtilis and avoiding the synthesis of the by-product acetoin; further, five exogenous reducing force metabolic reactions are introduced to replace the reaction of generating NADH in glycolysis pathway and tricarboxylic acid cycle to reconstruct intracellular reducing force metabolism, which specifically comprise glyceraldehyde-3-phosphate ferredoxin dehydrogenase, isocitrate NAD.sup.+ dehydrogenase, a malate quinone dehydrogenase, a ketoacid ferredoxin oxidoreductase and a nitrogenase ferritin. In a shake-flask fermentation process using a complex medium, acetylglucosamine yield of the recombinant strain BSGNKAP8 is 24.50 g/L, acetylglucosamine/glucose yield is 0.469 g/g, respectively 1.97 times and 2.13 times of those of the starting strain BSGNKAP2.

Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure.

The present invention relates to a novel carbon dioxide fixation cycle synthesizing a carbohydrate product from carbon dioxide in vitro. In addition, the present invention relates to a unit or a composition carrying out carbon dioxide fixation in cyclic manner. Additionally, the present invention relates to a method to fix carbon dioxide or a method to produce glyoxylate from the carbon dioxide fixation cycle. The present carbon dioxide fixation cycle is not found in natural world, and we found that, when the novel carbon dioxide fixation cycle is used, only three ATP molecules are consumed to fix one carbon dioxide molecule, and thus novel carbon dioxide fixation cycle has an energy conversion efficiency approximately 2.5 times higher than that of the Calvin cycle.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The present invention relates to a novel carbon dioxide fixation cycle synthesizing a carbohydrate product from carbon dioxide in vitro. In addition, the present invention relates to a unit or a composition carrying out carbon dioxide fixation in cyclic manner. Additionally, the present invention relates to a method to fix carbon dioxide or a method to produce glyoxylate from the carbon dioxide fixation cycle. The present carbon dioxide fixation cycle is not found in natural world, and we found that, when the novel carbon dioxide fixation cycle is used, only three ATP molecules are consumed to fix one carbon dioxide molecule, and thus novel carbon dioxide fixation cycle has an energy conversion efficiency approximately 2.5 times higher than that of the Calvin cycle.

The present invention provides for a method to increase production of isoprenol by a genetically modified Pseudomonas cell, the method comprising: (a) providing a genetically modified Pseudomonas cell comprising one or more of heterologous genes encoding: MvaE, AtoB, MvaS, MK, PMD.sub.HKQ, AphA, and PhoA; and (b) culturing or growing the genetically modified Pseudomonas cell in a medium to produce isoprenol; wherein (i) the genetically modified Pseudomonas cell is deleted, knocked out, or reduced in expression of one or more of the following endogenous genes: a gene at PP_2675 locus (or a deletion of the PP_2675 locus), phaABC, mvaB, hbdH, ldhA, gntZ, ppsA, pycAB, gltA, and aceA, and/or (ii) the medium comprises one or more amino acids that reduce the catabolism of isoprenol.